ADC Therapeutics SA PE Ratio 2019-2023 | ADCT
Current and historical p/e ratio for ADC Therapeutics SA (ADCT) from 2019 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. ADC Therapeutics SA PE ratio as of June 02, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| ADC Therapeutics SA PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-06-02 |
2.49 |
|
0.00 |
| 2023-03-31 |
1.95 |
$-2.53 |
0.00 |
| 2022-12-31 |
3.84 |
$-2.01 |
0.00 |
| 2022-09-30 |
4.82 |
$-2.16 |
0.00 |
| 2022-06-30 |
7.95 |
$-2.44 |
0.00 |
| 2022-03-31 |
14.69 |
$-2.55 |
0.00 |
| 2021-12-31 |
20.20 |
$-3.00 |
0.00 |
| 2021-09-30 |
27.16 |
$-3.28 |
0.00 |
| 2021-06-30 |
24.35 |
$-2.64 |
0.00 |
| 2021-03-31 |
24.41 |
$-3.70 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.191B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
